Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score.
Gino M DettorreSaoirse DollyAngela LoizidouJohn ChesterAmanda JacksonUma MukherjeeAlberto ZambelliJuan Aguilar-CompanyMark BowerChristopher C T SngRamon SalazarAlexia BertuzziJoan BrunetRicard MesiaAilsa Sita-LumsdenElia SeguíFederica BielloDaniele GeneraliSalvatore GrisantiPavetha SeevaGianpiero RizzoMichela LibertiniAntonio MaconiCharlotte MossBeth RussellNadia HarbeckBruno VincenziRossella BertulliDiego OttavianiRaquel LiñanAndrea MarrariM Carmen Carmona-GarcíaNeha ChopraCarlo Alberto TondiniOriol MirallasValeria TovazziVittoria FotiaClaudia Andrea CruzNadia Saoudi-GonzalezEudald FelipAriadna RoquéAlvin J X LeeTom Newsom-DavisDavid Garcia-IllescasRoxana ReyesYien Ning Sophia WongDaniela FerranteLorenza ScottiJavier Marco-HernándezIsabel Ruiz-CampsAndrea PatriarcaLorenza RimassaLorenzo ChiudinelliMichela FranchiArmando SantoroAleix PratAlessandra GennariMieke Van HemelrijckJosep TaberneroNikolaos DiamantisDavid James Pinatonull nullPublished in: Journal for immunotherapy of cancer (2021)
Systemic inflammation is a validated prognostic domain in SARS-CoV-2-infected patients with cancer and can be used as a bedside predictor of adverse outcome. Lymphocytopenia and hypoalbuminemia as computed by the OIS are independently predictive of severe COVID-19, supporting their use for risk stratification. Reversal of the COVID-19-induced proinflammatory state is a putative therapeutic strategy in patients with cancer.